Echo Therapeutics
Echo Therapeutics develops the Symphony tCGM System, a novel, non-invasive (needle-free) glucose monitoring system for diabetes patients.
Launch date
Employees
Woodbridge Township New Jersey (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | N/A | IPO | |
| N/A | $2.0m | Post IPO Equity | |
| N/A | $563k | Post IPO Equity | |
| N/A | $2.5m | Post IPO Equity | |
| N/A | $2.9m | Debt | |
| N/A | $2.9m | Debt | |
| N/A | $12.5m | Post IPO Equity | |
$10.0m | Post IPO Equity | ||
| N/A | $4.0m | Debt | |
| N/A | $1.8m | Debt | |
| Total Funding | - | ||
Related Content
Recent News about Echo Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.